公开(公告)号：US20230150972A1

公开(公告)日：2023-05-18

申请号：US17951549

申请日：2022-09-23

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Verner Alexander Lofstrand ,  Jung Yun Kim ,  Helen Clement ,  Kristen Nicole Burford ,  Paul Charifson ,  Michael Clark

IPC: C07D401/12 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14 ,  C07D413/12 ,  C07D403/12 ,  C07D211/56 ,  C07D405/12 ,  C07D498/08 ,  C07D487/08 ,  C07D471/08 ,  C07D487/10 ,  C07D407/14 ,  C07D417/12 ,  C07D498/04 ,  C07D401/04 ,  C07D497/08 ,  C07D239/42 ,  C07D409/14

CPC classification number: C07D401/12 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14 ,  C07D413/12 ,  C07D403/12 ,  C07D211/56 ,  C07D405/12 ,  C07D498/08 ,  C07D487/08 ,  C07D471/08 ,  C07D487/10 ,  C07D407/14 ,  C07D417/12 ,  C07D498/04 ,  C07D401/04 ,  C07D497/08 ,  C07D239/42 ,  C07D409/14

Abstract: The present disclosure is directed to compounds of formula (I):




wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US11325902B2

公开(公告)日：2022-05-10

申请号：US16927178

申请日：2020-07-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Kristen Nicole Burford ,  Thilo Focken ,  Verner Alexander Lofstrand ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/12 ,  A61P25/08 ,  C07D277/52 ,  C07D413/12

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20220064120A1

公开(公告)日：2022-03-03

申请号：US17368766

申请日：2021-07-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US11174268B2

公开(公告)日：2021-11-16

申请号：US16805895

申请日：2020-03-02

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  David Earl Bogucki ,  Kristen Nicole Burford ,  Sultan Chowdhury ,  Charles Jay Cohen ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Robert Joseph Devita ,  James Roy Empfield ,  Thilo Focken ,  Michael Edward Grimwood ,  Syed Abid Hasan ,  Qi Jia ,  James Philip Johnson, Jr. ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D491/107 ,  C07D493/10 ,  C07D237/20 ,  C07D213/76 ,  C07D239/69 ,  C07D261/16 ,  C07D263/50 ,  C07D275/03 ,  C07D277/52 ,  C07D285/08 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/10 ,  C07D417/14 ,  C07D451/06 ,  A61K31/395 ,  A61K31/427

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US11149002B2

公开(公告)日：2021-10-19

申请号：US16702286

申请日：2019-12-03

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Salvatore Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D207/16 ,  C07D403/12 ,  C07D413/14 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07C235/52 ,  C07D205/04 ,  C07D277/06 ,  C07D209/02 ,  C07D305/08 ,  C07D401/14 ,  C07D231/06 ,  C07D403/04 ,  C07D403/14 ,  C07D409/06 ,  C07D417/12 ,  C07D451/02 ,  C07D263/04 ,  C07D263/26 ,  C07C235/42 ,  C07C235/54 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D401/10 ,  C07D405/10 ,  C07D471/08

Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20210161886A1

公开(公告)日：2021-06-03

申请号：US17093183

申请日：2020-11-09

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Cynthia Louise HARDEN ,  Gregory N. BEATCH

IPC: A61K31/472 ,  A61P25/24 ,  A61K9/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US10981905B2

公开(公告)日：2021-04-20

申请号：US16556055

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D471/04 ,  A61K31/437 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US10815229B1

公开(公告)日：2020-10-27

申请号：US16821294

申请日：2020-03-17

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Kristen Nicole Burford ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Syed Abid Hasan

IPC: C07D451/06 ,  C07D403/12 ,  C07D213/76 ,  C07D237/20 ,  C07D239/69 ,  C07D413/12 ,  C07D417/14 ,  C07D261/16 ,  C07D493/10 ,  C07D277/52 ,  C07D285/08 ,  C07D401/12 ,  C07D417/12

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

公开(公告)号：US10526285B2

公开(公告)日：2020-01-07

申请号：US16150070

申请日：2018-10-02

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Salvatore Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D207/16 ,  C07D403/12 ,  C07D413/14 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07C235/52 ,  C07D205/04 ,  C07D277/06 ,  C07D209/02 ,  C07D305/08 ,  C07D401/14 ,  C07D231/06 ,  C07D403/04 ,  C07D403/14 ,  C07D409/06 ,  C07D417/12 ,  C07D451/02 ,  C07D263/04 ,  C07D263/26 ,  C07C235/42 ,  C07C235/54 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D401/10 ,  C07D405/10 ,  C07D471/08

Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10457654B2

公开(公告)日：2019-10-29

申请号：US15799771

申请日：2017-10-31

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Daniel Sutherlin ,  Steven McKerrall ,  Michael Scott Wilson ,  Kwong Wah Lai ,  Philippe Bergeron ,  Birong Zhang ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Liang Zhao ,  Claudio Sturino

IPC: C07D285/08 ,  C07D277/52 ,  C07D239/69 ,  C07D213/76 ,  C07D261/16 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  A61K31/427 ,  A61P19/02 ,  A61P29/00

Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.